Fundraising FoxLatterell Venture Partners
Venture capitalSan Ramon · Seed–Series A · 6 people tracked
Find your way into Latterell Venture Partners
Sign up to see every warm intro you have to Latterell Venture Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Latterell Venture Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Latterell Venture Partners backs early-stage healthcare companies developing innovative technologies addressing large markets, led by passionate entrepreneurs. The firm combines venture capital, entrepreneurial, technical, clinical, and collaborative expertise to help founders build successful startups. LVP aims to assemble a portfolio of leading biotechnology and medical device companies that generate strong returns for its limited partners while delivering major new disease treatments benefiting patients worldwide.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directoriesWhat they invest in
from 8 of 29 portfolio companiesBiotech ×7Healthtech ×5Medical Devices ×3Hardware ×1
HQs:United States×8
Investments · 29 tracked
founders shown can be your intro pathBy year:2018 · 22010 · 12005 · 25 dated
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)inGlendon E. French(Chief Executive Officer and Director)Derrick Sung(Chief Operating Officer and Chief Financial Officer)inGeoffrey Beran Rose(Chief Commercial Officer)
Co-investorsBand of AngelsHealthCapKaiser Permanente VenturesKleiner PerkinsMontreux Equity PartnersAlly Bridge Group
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalOUP (Osage University Partners)Agent CapitalBain Capital+3 more
Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis.
BiotechHealthtechMedical Devices
Cam L. Garner(Co-founder and Chairman)Matthew J. D'Onofrio(Co-founder & Chief Executive Officer)
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Co-investorsMPM BioImpactOrbiMedThe Vertical GroupVersant Ventures
Developed lightweight portable oxygen concentrators; acquired by ResMed.
HealthtechAustin, US
John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)
BoardGeoff Pardo(Director)inStephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)
Co-investorsGilde Healthcare
Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.
BiotechHardwareMedical Devices
Co-investorsIn-Q-TelQuestMark Partners
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)inAmin Khan(Executive Officer)inJames Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalSofinnova VenturesAdams Street Partners
Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease.
BiotechHealthtech
Co-investorsThe Vertical Group
Mountain View, US
Alan Jacobs(Executive Officer, Director)Jennifer Jacobs(Executive Officer, Director)
BoardJames Woody(Director)John Friedman(Director)Grace Colon(Director)Rodney Markin(Director)
Co-investorsEaston Capital
ProteinSimple developed instruments and consumables for protein analysis; acquired by Techne/Bio-Techne for $300M in 2014.
Co-investorsMitsui Global InvestmentThe Vertical Group
Developing cancer therapeutics based on apoptosis research; IPO'd December 2013.
Transcend Medical was a Menlo Park, CA medical-device company spun out of ForSight Labs that developed the CyPass Micro-Stent, a minimally invasive glaucoma implant to reduce intraocular pressure.
Menlo Park, US
Co-investorsCanaan PartnersLightstone Ventures
Viracta Therapeutics was a precision oncology company.
BiotechHealthtechCardiff, US
James Woody(Director)David Slack(Executive Officer)
BoardIvor Royston(Executive Officer, Director)Patrick Soon-Shiong(Director)Richard Ghalie(Director)
Co-investorsAisling CapitalaMoonVirtus Inspire Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CalistogaCellective TherapeuticsEnsure MedicalEvokeMeritageMeritage PharmaOncoMedOncoMed PharmaceuticalsPathwayPathway MedicalPetrolix WebsiteProteolixRevascular TherapeuticsTranscend
Exits · 15
1 IPOs · 14 acquisitions · showing 13Pulmonx Corp.NASDAQ: LUNGCalistogaacq. by GileadCellective Therapeuticsacq. by MedImmuneEnsure Medicalacq. by Johnson & JohnsonForteBioacq. by PallInova Labsacq. by ResMedIntegenXacq. by Thermo Fisher ScientificMeritageacq. by ShireOncoMed Websiteacq. by Mereo BioPharmaPathwayacq. by MedradProteolixacq. by Onyx PharmaceuticalsRevascular Therapeuticsacq. by Boston ScientificTranscendacq. by Alcon
Portfolio news
latest coverage across their companiesPulmonx Corp. · trysignalbase.com · May 12, 2026
Frequently asked questions
- How many investments has Latterell Venture Partners made?
- Latterell Venture Partners has 29 tracked investments, 15 of which have exited.
- What stage does Latterell Venture Partners invest at?
- Latterell Venture Partners invests at the Seed, Series A stages.
- What is Latterell Venture Partners's typical check size?
- Latterell Venture Partners typically writes checks of $50K – $10M.
- What sectors does Latterell Venture Partners focus on?
- Latterell Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Latterell Venture Partners located?
- Latterell Venture Partners is headquartered in San Ramon, US.
- Does Latterell Venture Partners lead rounds?
- Yes, Latterell Venture Partners leads investment rounds.
- Who does Latterell Venture Partners co-invest with?
- Latterell Venture Partners most often shares deals with The Vertical Group, Frazier Life Sciences, Lightstone Ventures, among 24 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.